Cytarabine vs Capecitabine — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Nucleoside Metabolic Inhibitor

Cytarabine

First FDA approval: 1990-06-04

Nucleoside Metabolic Inhibitor

Capecitabine

Brand: XELODA

First FDA approval: 1998-04-30

Lowest NADACAcquisition cost floor across all NDCs

—Per unit

$0.396Per unit

Average NADACAcross all dosage forms and strengths

—

$0.458Up to $0.510

Generic manufacturersActive ANDA holders — FDA Orange Book

715 total ANDAs filed

1122 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$557Full year

$74309Full year

Part D claims (CY24)Total fills, all strengths

4113 beneficiaries

24980 beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$14Per claim, all NDCs

$298Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

—Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

—None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes7 manufacturers

Yes11 manufacturers